50 results on '"Webb, Mason"'
Search Results
2. Cerebrospinal Fluid Liquid Biopsies in the Evaluation of Adult Gliomas
3. Belzutifan in adults with VHL-associated central nervous system hemangioblastoma: a single-center experience
4. Trap and ambush therapy using sequential primary and tumor escape-selective oncolytic viruses
5. Clinical experience and outcomes in patients with pineal parenchymal tumor of intermediate differentiation (PPTID): a single-institution analysis
6. 62-Year-Old Woman With Diarrhea, Vomiting, and Chest Pain
7. Isocitrate Dehydrogenase Inhibitors in Glioma: From Bench to Bedside
8. 28-Year-Old Man With an Enlarged Left Testicle
9. Antiangiogenic exclusion rules in glioma trials: Historical perspectives and guidance for future trial design
10. A case series of osseous metastases in patients with glioblastoma.
11. Immune Checkpoint Inhibitors and Glioblastoma: A Review on Current State and Future Directions.
12. Immune Checkpoint Inhibitors and Glioblastoma: A Review on Current State and Future Directions
13. CTIM-33. EFFICACY AND SAFETY STUDY OF NEOADJUVANT EFINEPTAKIN ALFA (NT-I7) AND PEMBROLIZUMAB IN RECURRENT GLIOBLASTOMA
14. RADT-18. PROTON CRANIOSPINAL IRRADIATION WITH CHECKPOINT INHIBITOR THERAPY FOR PATIENTS WITH LEPTOMENINGEAL DISEASE FROM SOLID TUMORS – A SINGLE INSTITUTION CASE SERIES
15. NCOG-37. BELZUTIFAN IN ADULTS WITH VHL-ASSOCIATED CENTRAL NERVOUS SYSTEM HEMANGIOBLASTOMA: A SINGLE-CENTER EXPERIENCE
16. Proton Craniospinal Irradiation with Immunotherapy in Two Patients with Leptomeningeal Disease from Melanoma
17. Safety of intravenous thrombolysis for ischemic stroke in patients with hematologic malignancies: A single institution experience
18. Proton Craniospinal Irradiation with Immunotherapy in Two Patients with Leptomeningeal Disease from Melanoma.
19. Current Status and Challenges of Oncolytic Virotherapy for the Treatment of Glioblastoma
20. Teaching NeuroImage: Intracranial Solitary Fibrous Tumor With Liver Metastasis
21. The Current Status, Challenges, and Future Potential of Therapeutic Vaccination in Glioblastoma
22. Data from Differential PI3Kδ Signaling in CD4+ T-cell Subsets Enables Selective Targeting of T Regulatory Cells to Enhance Cancer Immunotherapy
23. Supplementary figure S5 from Differential PI3Kδ Signaling in CD4+ T-cell Subsets Enables Selective Targeting of T Regulatory Cells to Enhance Cancer Immunotherapy
24. Supplemental Fig. 2 from Enhanced Therapeutic Efficacy and Memory of Tumor-Specific CD8 T Cells by Ex Vivo PI3K-δ Inhibition
25. Supplement Materials and Methods from Differential PI3Kδ Signaling in CD4+ T-cell Subsets Enables Selective Targeting of T Regulatory Cells to Enhance Cancer Immunotherapy
26. Data from Enhanced Therapeutic Efficacy and Memory of Tumor-Specific CD8 T Cells by Ex Vivo PI3K-δ Inhibition
27. Supplemental Fig. 4 from Enhanced Therapeutic Efficacy and Memory of Tumor-Specific CD8 T Cells by Ex Vivo PI3K-δ Inhibition
28. Supplemental Fig. 1 from Enhanced Therapeutic Efficacy and Memory of Tumor-Specific CD8 T Cells by Ex Vivo PI3K-δ Inhibition
29. Supplemental Figure 6 from Enhanced Therapeutic Efficacy and Memory of Tumor-Specific CD8 T Cells by Ex Vivo PI3K-δ Inhibition
30. Supplemental Fig. 3 from Enhanced Therapeutic Efficacy and Memory of Tumor-Specific CD8 T Cells by Ex Vivo PI3K-δ Inhibition
31. Supplementary table 1 from Differential PI3Kδ Signaling in CD4+ T-cell Subsets Enables Selective Targeting of T Regulatory Cells to Enhance Cancer Immunotherapy
32. Supplemental Figure 5 from Enhanced Therapeutic Efficacy and Memory of Tumor-Specific CD8 T Cells by Ex Vivo PI3K-δ Inhibition
33. Supplementary Figure Legends from Differential PI3Kδ Signaling in CD4+ T-cell Subsets Enables Selective Targeting of T Regulatory Cells to Enhance Cancer Immunotherapy
34. NCOG-35. A SINGLE INSTITUTION SERIES ON PINEAL PARENCHYMAL TUMORS OF INTERMEDIATE DIFFERENTIATION (PPTID)
35. LOCL-03 INTRATUMORAL DELIVERY OF CONDITIONALLY REPLICATIVE HUMAN ADENOVIRUS 657 EXPRESSING THE IMMUNE CO-STIMULATOR CD40L (CRAD657-CD40L) AS A POTENTIALLY PROMISING TREATMENT FOR RECURRENT PEDIATRIC HIGH GRADE GLIOMA
36. CBIO-18. TP53-MUTANT OLIGODENDROGLIOMA: A SINGLE INSTITUTION CASE SERIES
37. Ranbp2 haploinsufficiency mediates distinct cellular and biochemical phenotypes in brain and retinal dopaminergic and glia cells elicited by the Parkinsonian neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
38. HITLER'S FORGOTTEN PLAN TO WIN WORLD WAR II: ASSASSINATE STALIN, FDR AND WINSTON CHURCHILL
39. Antigen-Specific Antitumor Responses Induced by OX40 Agonist Are Enhanced by the IDO Inhibitor Indoximod
40. Enhanced Therapeutic Efficacy and Memory of Tumor-Specific CD8 T Cells by Ex Vivo PI3K-δ Inhibition
41. Differential PI3Kδ Signaling in CD4+ T-cell Subsets Enables Selective Targeting of T Regulatory Cells to Enhance Cancer Immunotherapy
42. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts
43. Efficacy and safety study of neoadjuvant efineptakin alfa (NT-I7) and pembrolizumab in recurrent glioblastoma.
44. Efficacy of function-enhanced, re-activatable, dual-specific CAR T cells pre-loaded with oncolytic virus for immunotherapy of high-grade glioma.
45. Proton craniospinal irradiation with bevacizumab and pembrolizumab for leptomeningeal disease: a case report
46. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts
47. Enhanced Therapeutic Efficacy and Memory of Tumor-Specific CD8 T Cells by Ex Vivo PI3K-δ Inhibition.
48. Cancer Immunotherapy Using AIRE Conditioning of the Tumor Epitopeome.
49. Chimerization of the Anti-Viral CD8 + T Cell Response with A Broad Anti-Tumor T Cell Response Reverses Inhibition of Checkpoint Blockade Therapy by Oncolytic Virotherapy.
50. Differential PI3Kδ Signaling in CD4 + T-cell Subsets Enables Selective Targeting of T Regulatory Cells to Enhance Cancer Immunotherapy.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.